PIT
01 Dec 2020
Trial Summary
This study aims to determine the maximum tolerated dose (MTD) and assess the efficacy of panitumumab, irinotecan and trifluridine/tipiracil when given in combination for participants with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC).
Acronym:
PIT
ACTRN/NCT /ethics:
ACTRN12617001190392
Scientific title:
An open label dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer.
Sponsor / Cooperative group:
The Queen Elizabeth Hospital
Trial & Patient Characteristics
| Cancer Type | Bowel and colon |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I; Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Colorectal cancer |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | - |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Dr Nimit Singhal |
| Recruitment Status | Recruiting |
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Professor Tim Price |
| Recruitment Status | Recruiting |
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Hannah Adelson |
| Hannah.adelson@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Professor Chris Karapetis |
| Recruitment Status | Recruiting |
| Hospital | Lyell McEwin Hospital |
|---|---|
| Clinical Trial Coordinator | Andy Phay |
| andy.phay@sa.gov.au | |
| Phone | 08 8282 0833 |
| Principal Investigator | Dr Rohit Joshi |
| Recruitment Status | Recruiting |